80100-47-6

Upstream product

• 23100-12-1 6-chloronicotinylaldehyde 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 1025482-61-4 3-(1-bromo-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenylpropanoic acid 
• 1025482-21-6 3-(1-(3-cyanophenyl)-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenyl-N-(thiazol-2-yl)propanamide 
• 1025482-29-4 C₂₇H₂₂N₆OS 
• 1025482-30-7 C₂₈H₂₃N₅OS 
• 1025482-31-8 C₂₇H₂₂N₆OS 
• 1025482-36-3 C₂₇H₂₅N₅O₂S 
• 1025482-32-9 C₂₇H₂₂F₂N₄OS 
• 1025482-33-0 C₂₆H₂₁F₂N₅OS 
• 1025482-34-1 C₂₇H₂₂ClFN₄OS 
• 1025482-35-2 C₂₆H₂₁ClFN₅OS 
• 1025482-51-2 3-(6-chloro-pyridin-3-yl)-2,2-dimethyl-3-phenyl-propionic acid methyl ester 
• 1025482-52-3 methyl 3-(6-cyanopyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-53-4 methyl 3-(6-(aminomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-54-5 methyl 3-(6-(formamidomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 

Relevant academic research and scientific papers

Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3- phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core

A series of heterocyclic glucocorticoid receptor (GR) modulators with 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core are described. Structure-activity relationships suggest a combination of H-bond acceptor and a 4-fluorophenyl moiety as being important structural components contributing to the glucocorticoid receptor binding and functional activity for this series of GR modulators.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(=O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(=O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(=O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.

2-halo-pyridines

2-Halo-pyridines of the general formula I STR1 wherein X is Cl or Br; A is =0 or STR2 Ar is phenyl or substituted phenyl of the general formula STR3 in which n is 0, 1, 2 or 3; R is alkyl C1-4, alkoxy C1-4, phenoxy, alkylthio C1-4, halogen especially F and Cl, OH or C6 H5 ; and their salts, addition compounds and precursors (prodrugs). Furthermore the invention is directed to the production of these compounds and pharmaceuticals containing them.